Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Garfield Heights, Ohio Clinical Trials

A listing of Garfield Heights, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (29) clinical trials

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor Nivolumab In Metastatic Clear Cell Renal Cell Cancer

This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart) in IL-2 eligible clear cell metastatic RCC (Renal Cell Carcinoma) subjects in combination with Nivolumab. Investigators hypothesize that concurrent PD-1 ...

Phase

6.32 miles

Learn More »

Carfilzomib Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

PRIMARY OBJECTIVES: I. To determine the safety of carfilzomib in combination with rituximab-cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) (CR-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and identify a recommended phase II dose (RP2D). (Phase I) SECONDARY OBJECTIVES: I. To determine if CR-CHOP improves the rates ...

Phase

6.32 miles

Learn More »

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Primary Objective To evaluate the safety and feasibility of hematopoietic stem cell transplant (HSCT) after treatment with fludarabine in adult patients with Sickle Cell Disease (SCD). Secondary Objective(s), in HSCT for SCD To evaluate the rates of disease-free and overall survival in both MSD and alternate graft donor (MUD, haploidentical, ...

Phase

6.32 miles

Learn More »

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

Phase

6.32 miles

Learn More »

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with CF. This study will also assess the delivery of the drug to bronchial epithelial cells following multiple doses of MRT5005, ...

Phase

6.32 miles

Learn More »

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Phase

6.34 miles

Learn More »

Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in subjects with relapsed or refractory multiple myeloma. This study will also assess ...

Phase

6.37 miles

Learn More »

Factor VIII Gene Therapy Study in Patients With Hemophilia A

The purpose of this study is to determine the safety and tolerability of the factor VIII gene transfer treatment with BAY 2599023 (DTX201) in individuals with severe hemophilia A.

Phase

6.37 miles

Learn More »

The FIERCE-22 study is a Phase 1b/2 study to evaluate the effectiveness and safety of vofatamab (B-701) in combination with the immunotherapy drug pembrolizumab in the treatment of subjects with Stage IV, locally advanced or metastatic FGFR3 wild-type (WT) or mutation positive UCC who have previously been treated with a ...

Phase

7.3 miles

Learn More »